MedTrace Logo

CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery

NCT02566525 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2021-08-20

Study results available
· View outcomes & findings →

Summary

Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorb® device.

Conditions

  • Elective Cardiac Surgery

Interventions

DEVICE

CytoSorb

Cytosorb device use during cardiopulmonary bypass

Sponsors & Collaborators

  • CytoSorbents, Inc

    lead INDUSTRY

Principal Investigators

  • Steve Sisk, MSc Pharm · CytSorbents

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-10-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02566525 on ClinicalTrials.gov